Fresh from a private placement that raised €77.8 million, ThromboGenics NV of Belgium is expanding its commercial presence in the US ahead of the expected regulatory approval later this year of its lead product for eye disease, ocriplasmin. ---Subscribe to MedNous to access this article--- Finance, Grants, Deals Company News
